Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Previously Marketed

3

Possibly Marketed Outside US

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Histamine H1 receptor

3

mucopolysaccharide metabolic process

2

response to oxidative stress

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

5

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1997

3

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Allergic conjunctivitis

3

Bronchopulmonary diseases

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

Palliative

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

3

CNS Penetrant

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Kanebo

3

Keck, J.

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

5

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

5

EVMPD

5

FDA UNII

5

PUBCHEM

5

SMS_ID

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

RESPIRATORY SYSTEM

1

SENSORY ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

COUGH AND COLD PREPARATIONS

1

OPHTHALMOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

DECONGESTANTS AND ANTIALLERGICS

1

EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Mucolytics

1

Other antiallergics

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

3

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 5 of 5 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

EMEDASTINE

9J1H7Y9OJV

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1997

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histamine H1 receptor

Conditions:

Allergic conjunctivitis

Emedastine is an antihistaminic agent, which was approved by FDA for the treatment of allergic conjunctivitis (Emadine brand name). The drug acts selectively on H1 receptors with lower affinity to H2 and H3 subtypes. Emedastine has a relatively unfav...

orable CNS effect profile. A small percentage of patients reported somnolence as an adverse effect after administration.

BROMHEXINE

Q1J152VB1P

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

response to oxidative stress

mucopolysaccharide metabolic process

Conditions:

Bronchopulmonary diseases

Bromhexine is used for conditions where there are a lot of thick mucus in the airways. Bromhexine acts on the mucus at the formative stages in the glands, within the mucus-secreting cells. Bromhexine disrupts the structure of acid mucopolysaccharide ...

fibres in mucoid sputum and produces a less viscous mucus, which is easier to expectorate. In addition, bromhexine has antioxidant properties. Occasional, mild side effects include: a feeling of fullness in the stomach (bloatedness), diarrhea, dizziness, headache, indigestion, nausea, sweating and skin rashes. Bromhexine may increase the concentration of concurrently administered antibiotics in bronchial secretions. No clinically relevant interactions with other medications have been reported.

EMEDASTINE MONOFUMARATE

1P089Y932J

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1997

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histamine H1 receptor

Conditions:

Allergic conjunctivitis

Emedastine is an antihistaminic agent, which was approved by FDA for the treatment of allergic conjunctivitis (Emadine brand name). The drug acts selectively on H1 receptors with lower affinity to H2 and H3 subtypes. Emedastine has a relatively unfav...

orable CNS effect profile. A small percentage of patients reported somnolence as an adverse effect after administration.

EMEDASTINE DIFUMARATE

42MB94QOSM

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1997

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histamine H1 receptor

Conditions:

Allergic conjunctivitis

Emedastine is an antihistaminic agent, which was approved by FDA for the treatment of allergic conjunctivitis (Emadine brand name). The drug acts selectively on H1 receptors with lower affinity to H2 and H3 subtypes. Emedastine has a relatively unfav...

orable CNS effect profile. A small percentage of patients reported somnolence as an adverse effect after administration.

BROMHEXINE HYDROCHLORIDE

YC2ZOM3Z8V

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

response to oxidative stress

mucopolysaccharide metabolic process

Conditions:

Bronchopulmonary diseases

Bromhexine is used for conditions where there are a lot of thick mucus in the airways. Bromhexine acts on the mucus at the formative stages in the glands, within the mucus-secreting cells. Bromhexine disrupts the structure of acid mucopolysaccharide ...

fibres in mucoid sputum and produces a less viscous mucus, which is easier to expectorate. In addition, bromhexine has antioxidant properties. Occasional, mild side effects include: a feeling of fullness in the stomach (bloatedness), diarrhea, dizziness, headache, indigestion, nausea, sweating and skin rashes. Bromhexine may increase the concentration of concurrently administered antibiotics in bronchial secretions. No clinically relevant interactions with other medications have been reported.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1